In conclusion, these findings suggest that macrophage-specific HO-1 inhibition significantly contributes to M1 shift and to the anti-tumor immune response and enhances sensitivity to Doc, though systemic HO-1 inhibition provides a more robust therapeutic outcome. The gene discussed is HMOX1; the disease is neoplasm.